Niraparib (Zejula, TESARO Inc., Waltham, Massachusetts, USA, formerly known as MK-4827) is an orally potent PARP inhibitor and the third FDA-approved PARPi in treating ovarian cancers. Here, PARP1 is linked to ovarian cancer.